Over 70 million Americans (1 in 5) have a form of joint disease, including OA and RA. Of those, approximately 700,000 knee replacements are performed yearly at a cost of $22 billion, and the market size is projected to increase to 3.4 million knee replacements yearly by 2030 (this does not include hip and other joints). Intra-articular therapies are required to be tried before a joint replacement, although they are not active in treating the disease, and in 2015 the global market for intra-articular therapies was $7 billion.
Rheumatoid arthritis impacts approximately 1.3 million Americans and 4.9 million people globally. The US spends more than $17 billion a year on biologics for various auto immune diseases since we currently do not have a test which accurately predicts drug responsiveness, and the global RA market is expected to increase to $29 billion in 2020. In 2013, three biologics – Humira, Remicade, and Enbrel – were ranked among the top-10 best-selling drugs in the world, with global revenues of $11.1 billion, $9.9 billion, and $8.9 billion respectively, “reflecting their groundbreaking clinical and commercial success.” But there’s no complete cure for RA and most RA drugs are part of disease-management therapy.